Patents Represented by Attorney William R. Majarian
-
Patent number: 7416846Abstract: The present invention relates to a vaccine composition comprising VLPs containing L1 proteins or functional L1 protein derivatives from HPV 16, HPV 18, HPV 31 and HPV 45 genotypes.Type: GrantFiled: May 10, 2007Date of Patent: August 26, 2008Assignee: GlaxoSmithKline Biologicals SAInventor: Martine Anne Cecile Wettendorff
-
Patent number: 7371390Abstract: Novel combined vaccine compositions are provided, comprising a hepatitis B viral antigen and optionally in addition one or more of the following: an EBV antigen, a hepatitis A antigen or inactivated attenuated virus, a herpes simplex viral antigen, a VZV antigen, a Toxoplasma gondii antigen. The vaccine compositions are formulated with an adjuvant which is a preferential stimulator of TH1 cell response such as 3D-MPL and QS21.Type: GrantFiled: November 8, 2004Date of Patent: May 13, 2008Assignee: SmithKline Beecham Biologicals s.a.Inventor: Martine Anne Cecile Wettendorff
-
Patent number: 7220551Abstract: Novel combined vaccine compositions are provided, comprising a herpes simplex virus (HSV) antigen and a HPV antigen and optionally in addition one or more of the following: an EBV antigen, a hepatitis A antigen or inactivated attenuated virus, a hepatitis B viral antigen, a VZV antigen, a HCMV antigen, Toxoplasma gondii antigen. The vaccine compositions are formulated with an adjuvant which is a preferential stimulator of TH1 cell response such as 3D-MPL and QS21.Type: GrantFiled: June 29, 2006Date of Patent: May 22, 2007Assignee: SmithKline Beecham Biologicals S.A.Inventor: Moncef Mohamed Slaoui
-
Patent number: 7217419Abstract: The present invention relates to a vaccine composition comprising VLPs containing L1 proteins or functional L1 protein derivatives from HPV 16, HPV 18, HPV 31 and HPV 45 genotypes.Type: GrantFiled: March 17, 2003Date of Patent: May 15, 2007Assignee: GlaxoSmithKline Biologicals SAInventor: Martine Anne Cecile Wettendorff
-
Patent number: 7214772Abstract: SAF-2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing SAF-2 polypeptides and polynucleotides in therapy, and diagnostic assays for such.Type: GrantFiled: July 8, 2004Date of Patent: May 8, 2007Assignees: SmithKline Beecham Corporation, Johns Hopkins UniversityInventors: Kristine K Kikly, Connie Lyn Erickson-Miller, Bruce Bochner, Robert Schleimer
-
Patent number: 7205125Abstract: The present invention relates to mixed VLPs, and to a process for the production of a mixed VLP, the VLPs comprising L1 proteins from at least 2 different types of human papillomavirus.Type: GrantFiled: March 17, 2003Date of Patent: April 17, 2007Assignee: GlaxoSmithKline Biologicals SAInventors: Jose Antonio Castillo, Michel Olivier Simon Christian Deschuyteneer
-
Patent number: 7122645Abstract: A quantitative PCR method has been developed for the simultaneous detection and quantitation of an agent in samples of biologically derived materials. Unlike conventional quantitative PCR detection methods, this assay allows for the detection of viable agents.Type: GrantFiled: March 27, 2001Date of Patent: October 17, 2006Assignee: SmithKline Beecham CorporationInventors: Haiyan Liu, Anthony S. Lubiniecki, Shing H. Mai, Amy A. Murnane, Leonard T. Olszewski, Gerardo A. Zapata
-
Patent number: 6991929Abstract: A process for the production of inactivated Hepatitis A virus substantially free of host cell contamination is described, the process comprising: a) culturing Hepatitis A virus and harvesting a Hepatitis A preparation; b) treating said Hepatitis A preparation with a protease; and thereafter c) separating intact virus from protease digested material; d) inactivating said virus. Also described are vaccines comprising the inactivated Hepatitis A virus, preferably in combination with strong adjuvants.Type: GrantFiled: October 8, 1999Date of Patent: January 31, 2006Assignee: SmithKline Beecham Biologicals S.A.Inventor: Erik D′Hondt
-
Patent number: 6936255Abstract: Novel combined vaccine compositions are provided, comprising a herpes simplex virus (HSV) antigen and a HPV antigen and optionally in addition one or more of the following: an EBV antigen, a hepatitis A antigen or inactivated attenuated virus, a hepatitis B viral antigen, a VZV antigen, a HCMV antigen, a Toxoplasma gondii antigen. The vaccine compositions are formulated with an adjuvant which is a preferential stimulator of TH1 cell response such as 3D-MPL and QS21.Type: GrantFiled: September 7, 2000Date of Patent: August 30, 2005Assignee: SmithKline Beecham Biologicals s.a.Inventor: Martine Anne Cecile Wettendorff
-
Patent number: 6899884Abstract: A new mumps vaccine is presented, comprising a homogeneous pure isolate derived from the Jeryl-Lynn strain of mumps virus. In a preferred embodiment of the invention the vaccine produces higher seroconversion and anitbody titres than know commercial vaccines.Type: GrantFiled: November 3, 2003Date of Patent: May 31, 2005Assignee: SmithKline Beecham Biologicals, s.a.Inventors: Nigel Maurice Harford, Brigitte Desiree Alberte Colau, Jean Didelez
-
Patent number: 6893644Abstract: A vaccine formulation for the treatment or prophylaxis of hepatitis, especially hepatitis, especially hepatitis B, infections is provided comprising the hepatitis antigen and a suitable carrier such as alum in combination with 3-O-deacylated monophosphoryl lipid. A combination vaccines including the vaccine formulation are also described.Type: GrantFiled: June 19, 2003Date of Patent: May 17, 2005Assignee: SmithKline Beecham Biologicals s.a.Inventors: Nathalie Marie-Josephe Claude Garcon-Johnson, Pierre Hauser, Clothilde Thiriart, Pierre Voet
-
Patent number: 6835712Abstract: Spermine:peptide-based surfactant compounds are disclosed. The compounds are based on a spermine backbone with peptide groups and optionally hydrocarbyl groups linked thereto. Uses of the spermine:peptide-based surfactant compounds and methods for their production are also disclosed.Type: GrantFiled: July 19, 2002Date of Patent: December 28, 2004Assignees: SmithKline Beecham p.l.c., Cambridge University Technical Services Ltd.Inventors: Patrick Camilleri, Philippe Guedat, Anthony John Kirby, Andreas Kremer
-
Patent number: 6692752Abstract: A method of administering a vaccine to females to prevent or treat infections associated with pathogens which cause sexually transmitted diseases is described. The vaccine comprises one or more antigens for the prevention or treatment of sexually transmitted diseases, for example an HSV glycoprotein D or an immunological fragment thereof, and an adjuvant, especially a TH-1 inducing adjuvant. The use of the vaccine components for the formulation of a vaccine composition for the prevention or treatment of sexually transmitted diseases in female subjects is also described.Type: GrantFiled: September 14, 2000Date of Patent: February 17, 2004Assignee: SmithKline Beecham Biologicals S.A.Inventors: Moncef Mohamed Slaoui, Pierre G. Vandepapeliere
-
Patent number: 6693167Abstract: New peptide-based Gemini compounds comprising two linked chains (a) each having: (1) a positively charged hydrophilic head, Q1 or Q2 formed from one or more amino acids and/or amines, (2) a central portion, P1 or P2, having a polypeptide backbone, and (3) a hydrophobic tail, R1 or R2, the central sections of each chain being linked together by bridge Y through residues in P1 and P2, are disclosed. Methods for their preparation and uses are also disclosed. Such uses include transfection of polynucleotides into cells in vivo.Type: GrantFiled: June 8, 2000Date of Patent: February 17, 2004Assignee: SmithKline Beecham p.l.c.Inventors: Patrick Camilleri, Andreas Kremer, Simon Quentyn John Rice
-
Patent number: 6656476Abstract: A new mumps vaccine is presented, comprising a homogeneous pure isolate derived from the Jeryl-Lynn strain of mumps virus.Type: GrantFiled: August 7, 2002Date of Patent: December 2, 2003Assignee: SmithKline Beecham Biologicals (S.A.)Inventors: Nigel Maurice Harford, Brigitte Desiree Alberte Colau, Jean Didelez
-
Patent number: 6620414Abstract: A vaccine formulation for the treatment or prophylaxis of hepatitis, especially hepatitis B, infections is provided comprising the hepatitis antigen and a suitable carrier such as alum in combination with 3-O-deacylated monophosphoryl lipid A. Combination vaccines including the vaccine formulation are also described.Type: GrantFiled: August 21, 2001Date of Patent: September 16, 2003Assignee: SmithKline Beecham Biologicals (s.a.)Inventors: Nathalie Marie-Josephe Claude Garcon-Johnson, Pierre Hauser, Clothilde Thiriart, Pierre Voet
-
Patent number: 6342224Abstract: The present invention relates to fusions proteins, comprising a protein or part of a protein that provides T helper epitopes and an antigen from a human-papilloma virus. In particular the invention relates to fusion proteins comprising an E6 or E7 protein from HPV strain 16 or 18 linked to protein D from Haemophilus influenza B. The invention also provides vaccine compositions that are useful in the treatment or prophylaxis of human papilloma induced tumours.Type: GrantFiled: February 18, 2000Date of Patent: January 29, 2002Assignee: SmithKline Beecham Biologicals, S.A.Inventors: Claudine Bruck, Teresa Cabezon Silva, Anne-Marie Eva Fernande Delisse, Catherine Marie Ghislaine Gerard, Angela Lombardo-Bencheikh
-
Patent number: 6281409Abstract: Promoters capable of driving fruit-specific expression of DNA sequences in transgenic blackcurrant and other non-climacteric fruit are presented.Type: GrantFiled: November 2, 1998Date of Patent: August 28, 2001Assignee: SmithKline Beecham P.L.C.Inventors: Mary Rose Woodhead, Mark Andrew Taylor, Rex Michael Brennan
-
Patent number: 6040427Abstract: The Bordetella pertussis toxin is genetically modified to express a toxin protein which is deficient in target-cell receptor binding and is used in a vaccine for protection against whooping cough.Type: GrantFiled: July 1, 1998Date of Patent: March 21, 2000Assignee: SmithKline Beecham BiologicalsInventors: Camille Locht, Yves Lobet